Compass Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based therapeutics targeting angiogenesis and the tumor microenvironment. The filing covers the three months ended March 31, 2024; financial statements are unaudited and presented under U.S. GAAP.
The principal clinical candidates are CTX-009, CTX-471 and CTX-8371. The company has no product revenue and continues to fund operations primarily through equity financings.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | Not applicable |
| Research and development expense | $9.5 million | $6.6 million | +$2.9 million, 43% |
| General and administrative expense | $3.2 million | $3.1 million | +$0.2 million, 6% |
| Total operating expenses | $12.8 million | $9.7 million | +$3.1 million, 31% |
| Other income | $2.0 million | $1.9 million | +$0.1 million, 7% |
| Net loss | $10.8 million | $7.8 million | Loss increased $3.0 million |
| Basic and diluted loss per share | $0.08 | $0.06 | Loss per share increased |
| Cash used in operating activities | $13.9 million | $12.2 million | Use increased $1.7 million |
Other income consisted entirely of interest income. No income tax expense was recorded in either period. The filing does not provide a meaningful operating margin because the company has no revenue; operating loss was $12.8 million in Q1 2024.
At March 31, 2024, cash and cash equivalents were $23.7 million, marketable securities were $132.6 million, and total cash, cash equivalents and marketable securities were approximately $156 million. Total liabilities were $4.1 million, consisting primarily of operating lease obligations and current operating liabilities. The filing reports no debt arrangements outstanding.
Accumulated deficit was $326.1 million at March 31, 2024, compared with $315.3 million at December 31, 2023. Stockholders’ equity was $157.1 million. Shares outstanding increased to 137.6 million from 127.7 million at year-end 2023.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 43%, primarily due to approximately $2.6 million of additional clinical expenses associated with CTX-009 and CTX-8371.
- CTX-009 program spending increased to $5.7 million from $3.9 million; CTX-471 spending increased to $1.1 million from $0.9 million; and CTX-8371 spending increased to $1.0 million from $0.5 million.
- Share-based compensation increased to $2.0 million from $1.3 million and represented a significant non-cash expense.
- Operating cash use increased to $13.9 million from $12.2 million.
- The company sold 9.8 million shares through its at-the-market program for $18.1 million of gross proceeds and $17.6 million of net proceeds. Financing activities provided $17.4 million of cash in Q1 2024, compared with $41 thousand in Q1 2023.
- Cash and cash equivalents declined by $0.6 million during the quarter, after operating cash use, net investment purchases, and equity financing.
Guidance, Outlook, Risks and Unusual Items
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into late 2026 based on current plans. The company expects to require additional funding to complete development programs and potentially commercialize products.
- Initial results from the Stage 1 CTX-009 Phase 2 colorectal cancer trial are expected by mid-2024.
- Top-line data from the randomized Phase 2/3 CTX-009 biliary tract cancer study is expected in the first quarter of 2025.
- The FDA granted Fast Track Designation in April 2024 for CTX-009 plus paclitaxel in previously treated metastatic or locally advanced biliary tract cancer.
- Compass plans to initiate a Phase 2 CTX-471 monotherapy study in biomarker-selected advanced melanoma patients in the second half of 2024. The CTX-8371 first patient was dosed in April 2024.
- The CTX-471 combination dose-escalation study reported no dose-limiting toxicities but no responses; the dose-expansion cohorts are ongoing.
- In April 2024, Elpiscience achieved a CTX-009 Phase 1 milestone, triggering a $1.0 million payment to Compass, subject to a $150 thousand sublicensing payment to ABL Bio.
- Marketable securities had $161 thousand of unrealized losses at March 31, 2024, which management considered temporary and primarily attributable to interest-rate changes.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, manufacturing and supply risks, competition, intellectual-property risks, reliance on collaborators, continued operating losses, and the need for additional financing that could dilute existing shareholders.
- The company reported no material legal proceedings. Management concluded that disclosure controls and procedures were effective as of March 31, 2024.
Important Facts for Investors to Verify
- Verify enrollment progress and mid-2024 Stage 1 results for the CTX-009 colorectal cancer trial.
- Monitor the CTX-009 biliary tract cancer Phase 2/3 trial and the expected first-quarter 2025 top-line data.
- Assess whether the stated late-2026 cash runway remains valid as clinical spending increases and results affect development plans.
- Review future ATM or other equity financing activity and its potential dilution, given the company’s continuing losses and lack of product revenue.
- Evaluate the CTX-471 combination study’s lack of observed responses and the risks associated with advancing the biomarker-selected melanoma program.
- Confirm the timing and receipt of the $1.0 million Elpiscience milestone and the related payment obligation to ABL Bio.
- Review licensing obligations, including potential development, regulatory and commercial milestones and royalties payable under the ABL Bio and Adimab agreements.